Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

PROteolysis-TArgeting Chimeras (PROTACs) have emerged as an innovative drug development platform. However, most PROTACs have been generated empirically because many determinants of PROTAC specificity and activity remain elusive. Through computational modelling of the entire NEDD8-VHL Cullin RING E3...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Dongwen, Pal, Pratik, Liu, Xingui, Jia, Yannan, Thummuri, Dinesh, Zhang, Peiyi, Hu, Wanyi, Pei, Jing, Zhang, Qi, Zhou, Shuo, Khan, Sajid, Zhang, Xuan, Hua, Nan, Yang, Qingping, Arango, Sebastian, Zhang, Weizhou, Nayak, Digant, Olsen, Shaun K., Weintraub, Susan T., Hromas, Robert, Konopleva, Marina, Yuan, Yaxia, Zheng, Guangrong, Zhou, Daohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617031/
https://www.ncbi.nlm.nih.gov/pubmed/34824248
http://dx.doi.org/10.1038/s41467-021-27210-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617031/
https://www.ncbi.nlm.nih.gov/pubmed/34824248
http://dx.doi.org/10.1038/s41467-021-27210-x

Ejemplares similares